H.R. 7871 · 119th Congress · Health

MVP Act

In committee1.4k words Introduced Mar 9, 2026 · Latest action Mar 9, 2026

How far it has goneStage 2 of 6
  1. IntroducedMar 9, 2026 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)

The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.

Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to issue guidance on how state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.

Congressional Research Service · summary of “Introduced in House” version · Mar 9, 2026

Who lobbies on it

8 organizations, more than 96% of House bills · 27 filings, incl. 17 naming only S. 1637 · Q2 2025–Q3 2026

These 8 organizations’ PACs gave $126K to 14 of the 19 members sponsoring or cosponsoring H.R. 7871 in the 2025–26 election cycle.

See who got it, from which PACs, and how they compare to the rest of the House → Pro

One square per quarter since introduction, oldest left. Filled = named H.R. 7871 or S. 1637 that quarter.

  1. America's Health Insurance Plans Inc (ahip) 6 of 6 quarters
    “…H.R. 7871 - MVP Act - Rep. Guthrie, Brett - Value-based purchasing arrangements in Medicaid H.R. 8375 - Medicare Advantage Improvement Act - Rep. Joyce, John - MA programmatic reforms H.R. 8377 - Stop Deadly Denials Act - Rep. Khanna, Ro - MA prior authorization prohibition H.R. 8875 - Improving Home Dialysis Act…”

    $11.3M lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both

  2. Alliance for Regenerative Medicine 4 of 6 quarters
    “…MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.”

    $360K lobbying spend in 2026 to date, all issuesQ1 2026 filing · names S. 1637 only

  3. Pharmaceutical Care Management Association 3 of 6 quarters
    “S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S. 2617/H.R. 1244; Reducing Drug Prices for Seniors Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 2800…”

    $9.5M lobbying spend in 2026 to date, all issuesQ3 2026 filing · names both

5 more organizations, every filingPROUpgrade

Organizations that named H.R. 7871 or its companion S. 1637 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Reports naming only S. 1637 are included and tagged. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Members sponsoring the companion, S. 1637, are counted on that bill’s page, not here. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Mar 9, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. Mar 9, 2026Introduced in House